M. D. Anderson Study First to Evaluate Prevalence, Impact of Off Label Chemotherapy in Breast Cancer
Drugs not always approved for reimbursement, despite shown to be efficacious
[ABSTRACT #1016]
ORLANDO – At some point during their care, more than one-third of metastatic breast cancer patients receive chemotherapy off label, the legal use of FDA-approved drugs in a different indication than for which they were approved, according to researchers at The University of Texas M. D. Anderson Cancer Center.
National Breast Cancer Coalition
National Cancer Institute
Prostate Cancer Foundation